Improvement in pain: 0 to 3 months' postintervention Improvement in pain was defined and measured differently in the 2 included studies: using a "stomach ache diary" and the Faces Pain Scale (Bieri 1990). · Children with recurrent abdominal pain
Fibre showed no clear difference in improvement in pain: 0 to 3 months' postintervention Improvement in… compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Changes in BMI and body weight 1. Dairy‐rich diet a. BMI z score [units]a · preschool children (aged 0 to 6 years) with overweight or obesity
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · lycopene
Lycopene (Cano-Carrillo 2014) contributes to the dietary supplements short-term symptom-relief comparison (12 RCTs, insufficient/contradictory); no separate lycopene symptom-relief estimate reported.
1 study · 50 participants
GRADE not reported
Change in QoL - depression (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (lycopene) changes change in QoL - depression (surrogate marker) compared with placebo (very low certainty).
1 finding from 1 review
QoL · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (lycopene) changes change in quality of life (QoL) compared with placebo (very low certainty).
1 finding from 1 review
Change in QoL - anxiety (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (lycopene) changes change in QoL - anxiety (surrogate marker) compared with placebo (very low certainty).
1 finding from 1 review
Recovery during intervention defined as achieving WHZ ≥ −2 and absence of oedema in 1 study; reaching a WHZ score > −2 and without oedema in 1 study; WHZ > −2 in 1 study; having a WHZ score ≥ 0 in 1 study; reaching 100% weight for height in 1 stud... · children aged 6 months‐5 years with SAM (and mixed HIV comorbidity), some of whom had been stabilised as inpatients pre‐trial
Standard ready‐to‐use therapeutic food (RUTF) provided at a dose… probably leads to higher recovery during intervention defined as achieving WHZ ≥ −2 and… compared with an alternative dietary approach (moderate certainty).
1 finding from 1 review
Relapse during intervention defined as admission to inpatient therapeutic care or recurrence of oedema or systematic infections during the study period, and dropouts during intervention period · children aged 6 months‐5 years with SAM (and mixed HIV comorbidity), some of whom had been stabilised as inpatients pre‐trial
It is very uncertain whether standard ready‐to‐use therapeutic food (RUTF) provided at a dose… changes relapse during intervention defined as admission to inpatient… compared with an alternative dietary approach (very low certainty).
1 finding from 1 review
Mortality during intervention · children aged 6 months‐5 years with SAM (and mixed HIV comorbidity), some of whom had been stabilised as inpatients pre‐trial
It is very uncertain whether standard ready‐to‐use therapeutic food (RUTF) provided at a dose… changes mortality during intervention compared with an alternative dietary approach (very low certainty).
1 finding from 1 review
Rate of weight gain (g/kg/day) · children aged 6 months‐5 years with SAM (and mixed HIV comorbidity), some of whom had been stabilised as inpatients pre‐trial
1 finding from 1 review
Recovery during intervention defined as WHZ > 0 in 1 study; 100% weight for height in 1 study · children aged 6 months‐5 years with SAM (1 study included HIV‐uninfected children; 1 study included HIV‐infected children), all of whom…
Standard ready‐to‐use therapeutic food (RUTF) provided at a dose… may leads to higher recovery during intervention defined as WHZ > 0 in 1 study; 100%… compared with as a supplement to the usual diet (low certainty).
1 finding from 1 review
Relapse during intervention defined as admission to inpatient therapeutic care or recurrence of oedema or systematic infections during the study period, and dropouts during intervention period · children aged 6 months‐5 years with SAM (1 study included HIV‐uninfected children; 1 study included HIV‐infected children), all of whom…
Standard ready‐to‐use therapeutic food (RUTF) provided at a dose… may leads to lower relapse during intervention defined as admission to inpatient… compared with as a supplement to the usual diet (low certainty).
1 finding from 1 review
Mortality during intervention · children aged 6 months‐5 years with SAM (1 study included HIV‐uninfected children; 1 study included HIV‐infected children), all of whom…
It is very uncertain whether standard ready‐to‐use therapeutic food (RUTF) provided at a dose… changes mortality during intervention compared with as a supplement to the usual diet (very low certainty).
1 finding from 1 review
Rate of weight gain (g/kg/day) · children aged 6 months‐5 years with SAM (1 study included HIV‐uninfected children; 1 study included HIV‐infected children), all of whom…
1 finding from 1 review
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects: exacerbation of symptoms · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (Catuama herbal compound) changes adverse effects: exacerbation of symptoms compared with placebo (very low certainty).
1 finding from 1 review
Somnolence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (Catuama herbal compound) changes adverse effects: drowsiness compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: insomnia · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (Catuama herbal compound) changes adverse effects: insomnia compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · Catuama
'Catuama' herbal compound (Spanemberg 2012) contributes to the dietary supplements short-term symptom-relief comparison (insufficient/contradictory); no separate estimate reported.
1 study · 72 participants
GRADE not reported